250 related articles for article (PubMed ID: 18084242)
1. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
Chalikonda S; Kivlen MH; O'Malley ME; Eric Dong XD; McCart JA; Gorry MC; Yin XY; Brown CK; Zeh HJ; Guo ZS; Bartlett DL
Cancer Gene Ther; 2008 Feb; 15(2):115-25. PubMed ID: 18084242
[TBL] [Abstract][Full Text] [Related]
2. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.
Hartkopf AD; Bossow S; Lampe J; Zimmermann M; Taran FA; Wallwiener D; Fehm T; Bitzer M; Lauer UM
Gynecol Oncol; 2013 Aug; 130(2):362-8. PubMed ID: 23676551
[TBL] [Abstract][Full Text] [Related]
3. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
Kurosaki H; Nakatake M; Sakamoto T; Kuwano N; Yamane M; Ishii K; Fujiwara Y; Nakamura T
Cells; 2021 Apr; 10(5):. PubMed ID: 33922406
[TBL] [Abstract][Full Text] [Related]
4. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
6. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.
Hung CF; Tsai YC; He L; Coukos G; Fodor I; Qin L; Levitsky H; Wu TC
Gene Ther; 2007 Jan; 14(1):20-9. PubMed ID: 16915291
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
8. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors.
Lun X; Ruan Y; Jayanthan A; Liu DJ; Singh A; Trippett T; Bell J; Forsyth P; Johnston RN; Narendran A
Mol Oncol; 2013 Oct; 7(5):944-54. PubMed ID: 23816608
[TBL] [Abstract][Full Text] [Related]
9. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer.
Isoda L; Sonoda-Fukuda E; Fujino H; Takarada T; Hasegawa K; Kasahara N; Kubo S
Anticancer Res; 2023 Dec; 43(12):5311-5317. PubMed ID: 38030176
[TBL] [Abstract][Full Text] [Related]
11. Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.
Ottolino-Perry K; Tang N; Head R; Ng C; Arulanandam R; Angarita FA; Acuna SA; Chen Y; Bell J; Dacosta RS; McCart JA
Int J Cancer; 2014 Feb; 134(3):717-30. PubMed ID: 23893655
[TBL] [Abstract][Full Text] [Related]
12. Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
Chang CL; Ma B; Pang X; Wu TC; Hung CF
Mol Ther; 2009 Aug; 17(8):1365-72. PubMed ID: 19471247
[TBL] [Abstract][Full Text] [Related]
13. Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines.
Berchtold S; Beil J; Raff C; Smirnow I; Schell M; D'Alvise J; Gross S; Lauer UM
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076270
[TBL] [Abstract][Full Text] [Related]
14. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.
Gnant MF; Puhlmann M; Alexander HR; Bartlett DL
Cancer Res; 1999 Jul; 59(14):3396-403. PubMed ID: 10416601
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus.
Foloppe J; Kintz J; Futin N; Findeli A; Cordier P; Schlesinger Y; Hoffmann C; Tosch C; Balloul JM; Erbs P
Gene Ther; 2008 Oct; 15(20):1361-71. PubMed ID: 18480846
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
[TBL] [Abstract][Full Text] [Related]
19. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
20. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
